



# Solid-phase synthesis of $\alpha$ -sulfonylamino amide derivatives based on Ugi-type condensation reaction using sulfonamides as amine input<sup>†</sup>

Eugene Campian, Boliang Lou\* and Hossain Saneii


Advanced SynTech, LLC, 9800 Bluegrass Parkway, Louisville, KY 40299 USA

Received 19 September 2002; accepted 23 September 2002

**Abstract**—A method for solid-phase synthesis of  $\alpha$ -sulfonylamino amides has been developed, which relies on a new Ugi-type 4-component condensation reaction involving arylsulfonamides as an amine input followed by removal of the acid moiety under the basic conditions. Either polymer-bound sulfonamides or carboxylic acids can be used in this reaction to afford structurally diverse products with good purity and in moderate to excellent yield. © 2002 Elsevier Science Ltd. All rights reserved.

The importance of multi-component reactions (MCR) has received increasing attention due to the recent emergence of combinatorial chemistry technology.<sup>1</sup> These reactions enable to introduce three or more different building blocks, in most cases, in a single chemical step to give products with multiple diversity points. The Ugi condensation reaction employs four

components including a carboxylic acid, an amine, an aldehyde and an isocyanide to construct an  $\alpha$ -acylamino amide in one step, which can subsequently be converted into the corresponding amino acid, ester, lactam, lactone, etc.<sup>2,3</sup> The versatility of the reaction has also been demonstrated in the solid-phase syntheses of a variety of biologically interesting heterocyclic



**Scheme 1.** Reagents and conditions: (a) 4-carboxybenzenesulfonamide (6 equiv.), DIC (6 equiv.) and HOBt (6 equiv.), DCM/DMF, 2 h; (b) R<sub>1</sub>CHO (10 equiv.), AcOH (10 equiv.), R<sub>2</sub>NC (10 equiv.), MeOH/THF (1:1), 60°C, 24 h; (c) 40% aq. MeNH<sub>2</sub>/THF (v/v, 1:1), rt, overnight; (d) 25% TFA in DCM, rt, 30 min; (e) R<sub>3</sub>OH (10 equiv.), PPh<sub>3</sub> (10 equiv.), DIAD (10 equiv.), THF, rt, 2 h.

**Keywords:** solid-phase synthesis; multi-component condensation reaction; sulfonamide.

\* Corresponding author. Tel.: 502-499-0122; fax: 502-499-0078; e-mail: [b.lou@advsynotech.com](mailto:b.lou@advsynotech.com)

<sup>†</sup> This work was presented at the 220th National Meeting of American Chemical Society, Washington, DC, August 20–24, 2000, Abstract ORGN 0227.

structures via post-Ugi transformations.<sup>4</sup> Our interest in broadening the scope of the known reaction and developing efficient methods for parallel synthesis of structurally diverse  $\alpha$ -sulfonylamino amide derivatives<sup>5</sup> prompted us to investigate the condensation reaction in the presence of sulfonamides instead of amines.

The reactivity of the sulfonamides towards the Ugi-type condensation was initially examined in solution phase. *p*-Toluenesulfonamide was treated with HOAc (1 equiv.), hydrocinnamaldehyde (1 equiv.) and *t*-butyl isocyanide (1 equiv.) in THF and MeOH (v/v, 1:1) for 3 days to give a complex mixture with a majority of the unreacted sulfonamide and a trace amount of the desired four-component condensation product. This result encouraged us to attempt the solid-phase approach.

As shown in Scheme 1, resin-bound benzenesulfonamide **1** was prepared by coupling 4-carboxybenzenesulfonamide onto Rink resin<sup>6</sup> by using the DIC/HOBt coupling protocol. Subsequently, it was treated with HOAc (10 equiv.), hydrocinnamaldehyde (10 equiv.) and *t*-butyl isocyanide (10 equiv.) in the same solvent system (THF/MeOH, 1:1) at rt for 3 days. The formation of the desired product was unambiguously confirmed by LC–MS analysis upon cleavage with 20%

TFA in DCM, however, most of the starting sulfonamide was recovered. The reaction was then examined at 60°C for 24 h to give a mixture of the expected Ugi-products, *N*-acetyl  $\alpha$ -sulfonylamino amides (**2a** and/or **2b**), and a small amount of deacetylated product **3**. The acetyl moiety on the products **2a** and/or **2b** was readily removed by treating the resin with a 1:1 mixture of 40% aq. MeNH<sub>2</sub> and THF, leading to the complete conversion into the resin-bound sulfonamides **3**. The corresponding  $\alpha$ -sulfonylamino amides **4** were obtained upon cleavage from the resin by the standard TFA treatment.


The above condition was found to be applicable for a broad range of aldehydes and isocyanides as illustrated in Table 1 (**4a–j**,<sup>7</sup> entries 1–10). More importantly, the diversity of the products was further expanded by *N*-alkylation of **3** with various alcohols under the Mitsunobu conditions to afford *N*-alkylated products **5** which were then cleaved by TFA to give the products **6** in good yield as exemplified by **6a–c**<sup>8</sup> in Table 1 (entries 11–13).

An alternative approach was examined with a polymer-bound carboxylic acid in this new condensation reaction. Carboxypolystyrene<sup>6</sup> was treated with various arylsulfonamides in the presence of hydrocinnamaldehyde

Table 1.

Entry	Product	Purity <sup>c</sup>	Yield	Entry	Product	Purity <sup>c</sup>	Yield	
1	<b>4a</b> R <sub>1</sub> =	R <sub>2</sub> =	90%	89% <sup>b</sup>	10	<b>4j</b> R <sub>1</sub> =  R <sub>2</sub> =	70%	87% <sup>a</sup>
2	<b>4b</b> R <sub>1</sub> =	R <sub>2</sub> =	95%	>95% <sup>a</sup>	11	<b>6a</b> R <sub>3</sub> = Me	85%	82% <sup>b</sup>
3	<b>4c</b> R <sub>1</sub> =	R <sub>2</sub> =	90%	>95% <sup>a</sup>	12	<b>6b</b> R <sub>3</sub> =	85%	83% <sup>b</sup>
4	<b>4d</b> R <sub>1</sub> =	R <sub>2</sub> =	60% <sup>d</sup>	>90% <sup>a</sup> (63% <sup>b</sup> )	13	<b>6c</b> R <sub>3</sub> =	60%	77% <sup>a</sup>
5	<b>4e</b> R <sub>1</sub> =	R <sub>2</sub> =	90%	94% <sup>b</sup>	14	<b>8a</b> Ar =	65%	52% <sup>b</sup>
6	<b>4f</b> R <sub>1</sub> =	R <sub>2</sub> =	95%	90% <sup>b</sup>	15	<b>8b</b> Ar =	75%	87% <sup>b</sup>
7	<b>4g</b> R <sub>1</sub> =	R <sub>2</sub> =	95%	90% <sup>b</sup>	16	<b>8c</b> Ar =	75%	93% <sup>b</sup>
8	<b>4h</b> R <sub>1</sub> =	R <sub>2</sub> =	75%	60% <sup>b</sup>	17	<b>8d</b> Ar =	80%	90% <sup>b</sup>
9	<b>4i</b> R <sub>1</sub> =	R <sub>2</sub> =	60%	40% <sup>b</sup>	18	<b>8e</b> Ar =	85%	80% <sup>b</sup>

<sup>a</sup> determined by weight of the crude products based on the loading of the resins. <sup>b</sup> isolated yields. <sup>c</sup> determined by LC–MS using both UV and ELS detectors; further confirmed by <sup>1</sup>HNMR analysis. <sup>d</sup> a significant amount of unreacted sulfonamide recovered.



**Scheme 2.** Reagents and conditions: (a) hydrocinnamaldehyde (10 equiv.), arylsulfonamide (10 equiv.) and *t*-butyl isocyanide (10 equiv.), THF/MeOH, 60°C, 24 h; (b) 40% aq. MeNH<sub>2</sub>/THF (v/v, 1:1), rt, overnight.

hyde and *t*-butyl isocyanide at 60°C for 24 h in the same solvent system (THF/MeOH) as illustrated in Scheme 2. A traceless cleavage strategy was applied by treating the resin **7** with MeNH<sub>2</sub> in H<sub>2</sub>O/THF to release the desired  $\alpha$ -sulfonylamino amide derivatives **8** which are structurally complementary to the products obtained from the first approach described in Scheme 1. A set of representative examples is shown in Table 1 (**8a–e**,<sup>9</sup> entries 14–18).

In conclusion, an efficient method for the solid-phase construction of  $\alpha$ -sulfonylamino amides has been developed by utilizing arylsulfonamides instead of amines in the Ugi four-component condensation reaction. These two approaches, utilizing polymer-bound arylsulfonamides and carboxylic acids, allow a quick access to the corresponding compound libraries with a high degree of structural diversity. The further chemical manipulation leading to other biologically important core structures is under investigation.

### Acknowledgements

The authors would like to thank Ms. Michelle Richards for providing analytical support and Dr. Adnan Mjalli for his suggestions at the initial stage of the work.

### References

- Weber, L. *Drug Disc. Today* **2002**, *7*, 143–147.
- For a recent review, see: Dömling, A.; Ugi, I. *Angew. Chem., Int. Ed.* **2000**, *39*, 3168–3210.
- For representative examples, see: (a) Demharter, A.; Hörl, W.; Herdtweck, E.; Ugi, I. *Angew. Chem., Int. Ed.* **1996**, *35*, 173–175; (b) Keating, T. A.; Armstrong, R. W. *J. Am. Chem. Soc.* **1996**, *118*, 2574–2583; (c) Park, S. J.; Keum, G.; Kang, S. Bang.; Koh, H. Y.; Kim, Y.; Lee, D. H. *Tetrahedron Lett.* **1998**, *39*, 7109–7112; (d) Zhang, J.; Jacobson, A.; Rusche, J. R.; Herlihy, W. *J. Org. Chem.* **1999**, *64*, 1074–1076; (e) Gedey, S.; Van der Eycken, J.; Fülöp, F. *Org. Lett.* **2002**, *4*, 1967–1969.
- For representative examples, see: (a) Zhang, C.; Moran, E. J.; Woiwode, T. F.; Short, K. M.; Mjalli, A. M. M. *Tetrahedron Lett.* **1996**, *37*, 751–754; (b) Szardenings, A. K.; Burkoth, T. S.; Lu, H. H.; Tien, D. W.; Campbell, D. A. *Tetrahedron* **1997**, *53*, 6573–6593; (c) Lee, D.; Sello, J. K.; Schreiber, S. L. *Org. Lett.* **2000**, *2*, 709–712; (d) Hulme, C.; Ma, L.; Kumar, N. V.; Krolkowski, P. H.; Allen, A. C.; Labaudiniere, R. *Tetrahedron Lett.* **2000**, *41*, 1509–1514.
- For very recent examples of bioactive peptidomimetics containing  $\alpha$ -sulfonylamino amide moieties, see: (a) Das, J. Kimball, S. D.; Reid, J. A.; Wang, T. C.; Lau, W. F. Roberts, D. G. M.; Seiler, S. M.; Schumacher, W. A.; Ogletree, M. L. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 41–44; (b) Lin, L. S.; Kopka, I. E.; Mumford, R. A.; Magriotis, P. A.; Lanza, T., Jr.; Durette, P. L.; Kamenecka, T.; Young, D. N.; de Laszlo, S. E.; McCauley, E.; Van Riper, G.; Kidambi, U.; Egger, L. A.; Tong, X.; Lyons, K.; Vincent, S.; Stearns, R.; Colletti, A.; Teffera, Y.; Fenyk-Melody, J.; Schmidt, J. A.; MacCoss, M.; Hagmann, W. K. *Bioorg. Med. Chem. Lett.* **2002**, *12*, 611–614.
- Advanced ChemTech, Louisville, KY (800) 456–1403.
- General procedures for the preparation of compounds **4a–j**:  
Aminosulfonylbenzamide Rink resin **1** (1 g, 0.5 mmol /g) in a 40 mL vial was swelled with 2.5 mL of THF. To this mixture were then added solutions of 1 M hydrocinnamaldehyde in MeOH (5 mL, 10 equiv.), 1 M AcOH in THF (5 mL, 10 equiv.) and 2 M *t*-butyl isocyanide in MeOH (2.5 mL, 10 equiv.). The suspension was mixed on an ACT Labmate<sup>6</sup> at 60°C for 24 h. The resin was filtered, washed with DMF (3 $\times$ ), MeOH (3 $\times$ ) and DCM (3 $\times$ ). After drying, the resin was treated with a mixture of 40% aq. MeNH<sub>2</sub> and THF (10 mL, 1:1) at rt overnight. The resin was filtered, washed as usual and dried in vacuo (1.15 g). The dried resin **3a** (115 mg) was treated with 25% TFA in DCM for 30 min. The cleavage solution was evaporated to give a residue which was re-dissolved in acetonitrile. The solvent was then removed on a rotavapor to give the crude product (25.4 mg), which was purified by preparative TLC to give the pure product (18.6 mg, 89% yield). <sup>1</sup>H NMR (CD<sub>3</sub>OD): **4a**:  $\delta$  7.94–8.11 (m, 4H), 7.10–7.32 (m, 5H), 3.78–3.85 (m, 1H), 2.73 (m, 1H), 2.61 (m, 1H), 1.94 (m, 1H), 1.86 (m, 1H), 1.15 (s, 9H). **4h**:  $\delta$  8.00 (d, *J*=8.5 Hz, 2H), 7.86 (d, *J*=8.5 Hz, 2H), 7.09–7.24 (m, 5H), 3.75–3.77 (dd, 1H), 3.28 (m, 1H), 2.63–2.68 (m, 1H), 2.49–2.55 (m, 1H), 0.90–1.90 (m, 12H). **4i**: 7.98 (d, *J*=8 Hz, 2H), 7.91 (d, *J*=8 Hz, 2H), 7.03–7.27 (m, 10H), 4.16 (d, *J*=12 Hz, 1H), 4.10 (d, *J*=12 Hz, 1H), 3.81 (m, 1H), 1.35 (m, 2H), 0.92 (m, 2H).
- General procedures for the preparation of compounds **6a–c**:  
To the above resin-bound product **3a** (200 mg, ~0.087 mmol) placed in an 8 mL vial, were added solutions of 2 M methanol in THF (10 equiv.), 1 M triphenylphosphine in THF (10 equiv.) and 1 M DIAD in THF (10 equiv.). The suspension was mixed on an ACT Labmate at rt for 5 h. The resin was filtered, washed as usual and dried. The obtained resin was treated with 25% TFA in DCM for 30 minutes. The cleavage solution was evaporated to give a residue which was re-dissolved in acetonitrile. The solvent was then removed on a rotavapor to give the crude

product **6a** (85% purity), which was purified by preparative TLC to give the pure product (30.7 mg, 82% yield). <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 8.04 (d, *J* = 7 Hz, 2H), 7.89 (d, *J* = 7 Hz, 2H), 7.11–7.38 (m, 5H), 4.38 (t, 1H), 3.00 (s, 3H), 2.50 (t, 2H), 1.97–2.01 (m, 1H), 1.70–1.74 (m, 1H), 1.21 (s, 9H). **6b**: δ 8.00 (d, *J* = 8 Hz, 2H), 7.88 (d, *J* = 8 Hz, 2H), 6.99–7.32 (m, 10H), 4.45–4.53 (dd, *J* = 11.50 Hz, 2H), 4.21–4.24 (m, 1H), 3.80 (m, 1H), 3.68 (m, 2H), 3.53–3.56 (m, 1H), 1H), 2.46 (m, 2H), 2.06 (m, 1H), 1.68 (m, 1H), 1.21 (s, 9H).

9. General procedures for the preparation of compounds **8a–e**: To carboxypolystyrene resin (100 mg, 1 mmol/g) were added solutions of 1 M benzenesulfonamide in THF (1 mL, 10 equiv.), 2 M hydrocinnamaldehyde in MeOH (0.5 mL, 10 equiv.) and 2 M *t*-butyl isocyanide in MeOH (0.5 mL, 10 equiv.). The suspension was mixed on an ACT Labmate at

60°C for 24 h. The resin was filtered, washed as usual and dried. The resin was then treated with a mixture of 40% aqueous methylamine and THF (1:1, 2 mL) at rt for 12 h. The resin was filtered and rinsed with THF (4 mL). The combined filtrates were concentrated to give the crude product **8a** (65% purity), which was purified by preparative TLC to give the pure product (19.4 mg, 52% yield). <sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 7.53–7.87 (m, 5H), 7.08–7.24 (m, 5H), 3.74 (t, 1H), 2.64 (m, 1H), 2.48 (m, 1H), 1.86 (m, 1H), 1.75 (m, 1H), 1.14 (s, 9H). **8b**: δ 8.35–7.13 (m, 9H), 3.894 (m, 1H), 2.64 (m, 1H), 2.69 (t, 2H), 2.01 (m, 1H), 1.82 (m, 1H), 1.75 (m, 1H), 1.36 (s, 9H). **8c**: δ 8.08 (d, *J* = 8 Hz, 1H), 7.91 (d, *J* = 8 Hz, 1H), 7.74–7.83 (m, 2H), 7.13–7.25 (m, 5H), 3.92 (m, 1H), 2.71 (m, 1H), 2.58 (m, 1H), 1.95 (m, 1H), 1.88 (m, 1H), 1.11 (s, 9H).